# Neoadjuvant Listeria or Daratumumab in Prostate Cancer

> **NCT03035357** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Malignant Neoplasms of Male Genital Organs
- Prostate Cancer

## Interventions

- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT03035357
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-03-01
- **Primary completion:** 2019-03-01
- **Final completion:** 2019-03-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI's Request
- **Last updated:** 2024-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03035357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03035357, "Neoadjuvant Listeria or Daratumumab in Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03035357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*